Viela Bio

Investors/Media

Press Releases

Press Releases

11.10.2020
Viela Bio Reports Third Quarter 2020 Financial Results and Program Highlights
Company to host investor conference call and webcast today at 5:00 pm EST GAITHERSBURG, Md. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- Viela Bio  (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory
11.05.2020
Viela Bio Announces Final Results from Phase 1b Trial of VIB7734 in Patients with Cutaneous Lupus Erythematosus
-- VIB7734 potently depleted   blood and   tissue resident plasmacytoid dendritic cells, an important source of inflammatory mediators in autoimmune diseases   -- -- Treatment with VIB7734 resulted in clinically significant reduction in CLASI-A , a clinical measure of cutaneous lupus lesions -- --
11.02.2020
Viela Bio to Webcast Third Quarter 2020 Financial Results and Program Highlights on November 10, 2020
GAITHERSBURG, Md. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Viela Bio  (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today announced it will host a webcast and conference call
9.03.2020
Viela Bio Announces Data Presentations at the 8th Joint ACTRIMS-ECTRIMS Meeting, MS Virtual 2020
GAITHERSBURG, Md. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today announced that four abstracts have been accepted for
8.12.2020
Viela Bio Reports Second Quarter 2020 Financial Results and Program Highlights
Company to host investor conference call and webcast today at 5:00 pm ET GAITHERSBURG, Md. , Aug. 12, 2020 (GLOBE NEWSWIRE) -- Viela Bio  (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory
8.05.2020
Viela Bio to Webcast Second Quarter 2020 Financial Results and Program Highlights on August 12, 2020
GAITHERSBURG, Md. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today announced it will host a webcast and conference call
6.11.2020
Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
UPLIZNA™ is the first and only B cell depleter approved for the treatment of NMOSD in adults who are anti-aquaporin-4 (AQP4) antibody positive GAITHERSBURG, Md. , June 11, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE) today announced that the U.S. Food and Drug Administration (FDA) has approved
5.27.2020
Viela Bio Announces Pricing of Public Offering of Common Stock
GAITHERSBURG, Md., May 27, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq: VIE ), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at
5.27.2020
Viela Bio Announces Pricing of Public Offering of Common Stock
GAITHERSBURG, Md. , May 27, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at
5.26.2020
Viela Bio Announces Proposed Public Offering of Common Stock
GAITHERSBURG, Md. , May 26, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced that it intends to offer and sell, subject to market and other conditions, 3,000,000
Displaying 1 - 10 of 16

Shareholder Tools